Terminated PHASE2 INTERVENTIONAL 2-arm NCT01871480

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

An Open-label, Randomized, Controlled Study of Gefitinib Plus Autologous Cytokine-Induced Killer Cell Immunotherapy（CIK）Versus Gefitinib Alone As Second Or Third-Line Treatment in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Sponsor: Kunming Medical University

Conditions Non-Small Cell Lung Cancer

Interventions Group A:cytokine-induced killer cell +gefitinib Group B:Gefitinib

Updated 5 times since 2017 Last updated: Dec 26, 2013 Started: May 31, 2013 Primary completion: Nov 30, 2015 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other Non-Small Cell Lung Cancer trials with similar outcome

Browse all Non-Small Cell Lung Cancer trials

Listed as NCT01871480, this PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Kunming Medical University, it has been updated 5 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kunming Medical University

Data source: Kunming Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kunming, China